Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Wagner, J. L., H. J. Deeg, K. Seidel, C. Anasetti, K. Doney, J. Sanders, K. M. Sullivan, and R. Storb. “Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience..” Transplantation 61, no. 1 (January 15, 1996): 54–61. https://doi.org/10.1097/00007890-199601150-00012.

PMID
8560574
Full Text

Anderson, J. E., F. R. Appelbaum, G. Schoch, T. Gooley, C. Anasetti, W. I. Bensinger, E. Bryant, C. D. Buckner, T. Chauncey, and R. A. Clift. “Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors..” J Clin Oncol 14, no. 1 (January 1996): 220–26. https://doi.org/10.1200/JCO.1996.14.1.220.

PMID
8558201
Full Text

Sullivan, K. M. “Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin..” Clin Ther 18 Suppl B (1996): 126–36. https://doi.org/10.1016/s0149-2918(96)80204-9.

PMID
8930450
Full Text

Deeg, H. J., G. Socié, G. Schoch, M. Henry-Amar, R. P. Witherspoon, A. Devergie, K. M. Sullivan, E. Gluckman, and R. Storb. “Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients..” Blood 87, no. 1 (January 1, 1996): 386–92.

PMID
8547667
Scholars@Duke

Anderson, J. E., F. R. Appelbaum, G. Schoch, T. Gooley, C. Anasetti, W. I. Bensinger, E. Bryant, et al. “Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors..” Blood 87, no. 1 (January 1, 1996): 51–58.

PMID
8547676
Scholars@Duke

Sullivan, K. “IVIG in bone marrow transplantation.” P and T 21, no. 4 SUPPL. (January 1, 1996).

Scholars@Duke

Balduzzi, A., T. Gooley, C. Anasetti, J. E. Sanders, P. J. Martin, E. W. Petersdorf, F. R. Appelbaum, et al. “Unrelated donor marrow transplantation in children..” Blood 86, no. 8 (October 15, 1995): 3247–56.

PMID
7579422
Scholars@Duke

Kalhs, P., I. Schwarzinger, G. Anderson, M. Mori, R. A. Clift, R. Storb, C. D. Buckner, F. R. Appelbaum, J. A. Hansen, and K. M. Sullivan. “A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia..” Blood 86, no. 5 (September 1, 1995): 2028–32.

PMID
7655031
Scholars@Duke

Storb, R., C. Anasetti, F. R. Appelbaum, H. J. Deeg, K. Doney, P. Martin, R. Nash, K. Sullivan, and R. Witherpoon. “Immunosuppressive agents for prevention of graft-versus-host disease.” Bone Marrow Transplantation 15, no. SUPPL. 1 (July 26, 1995).

Scholars@Duke

Doney, K. C., R. Storb, K. Beach, C. Anasetti, H. J. Deeg, J. A. Hansen, P. J. Martin, R. A. Nash, M. M. Schubert, and K. M. Sullivan. “A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants..” Transplantation 60, no. 1 (July 15, 1995): 55–58. https://doi.org/10.1097/00007890-199507150-00011.

PMID
7624943
Full Text

Pages